NCT02571530View on ClinicalTrials.gov

Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer

PHASE1TerminatedINTERVENTIONAL

Enrollment

2

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions

Neoplasm Metastasis

Interventions

DRUG

Intra-arterial Cerebral Infusion of Trastuzumab

Trial Locations (1)

10075

Lenox Hill Brain Tumor Center, New York

Sponsors

Lead Sponsor

Northwell Health

All Listed Sponsors

lead

Northwell Health

OTHER

NCT02571530 - Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer | Biotech Hunter | Biotech Hunter